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Abstract The combination of different therapeutic modalities 
is a promising option to combat tumour recurrence.  PolyLactic 
and Glycolic Acid nanoparticles are exploited for the simultaneous 
delivery of a boron-curcumin complex (RbCur) and an amphiphilic 
Gd complex into tumour cells with the aim of performing Boron 
and Gadolinium Neutron Capture Therapy (NCT) in combination 
with an additional curcumin anti-proliferative effect. Furthermore, 
the use of Gd complexes allows the MRI assessment of the 
amount of B and Gd internalized by tumour cells. PLGA 
nanoparticles are targeted to ovarian cancer cells (IGROV-1), by 
including in the formulation a pegylated phospholipid 
functionalized with the folate moiety. NCT is performed on 
IGROV-1 cells internalizing 6.4 and 78.6 µg/g of 10B and 157Gd, 
respectively. The synergic action of neutron treatment and 
curcumin cytotoxicity results in a significant therapeutic 
improvement.  
Introduction 
In recent years, much attention has been devoted to the use of 
combinations of different therapeutic modalities, as possible 
strategies to treat cancer.[1] This relies on the evidence that 
although a large majority of chemotherapeutic protocols and 
radiotherapies can considerably reduce tumour masses, they 
often fail in causing their complete regression as shown by a high 
number of tumour recurrence cases.[2] Moreover, the time-
dependent development of chemoresistance and radioresistance 
by a minor cell population within the tumour and the nonspecific 
toxicity toward normal cells are the other major limitations of 
standard therapies.[2-3] There is now an approved view that 
complete tumour regression can be achieved by the combination 
of different therapeutic strategies whereas a reduction in the off 
target toxicity can be tackled by developing target-specific drugs 
endowed with reduced adverse effects or by using a more specific 
radiotherapeutic protocol able to discriminate between healthy 
and cancer cells.  
Boron Neutron Capture Therapy (BNCT) is a non-conventional 
radiotherapy that combines low energy neutron irradiation with 
the presence of boron-containing compound at the targeted cells. 
Neutrons are captured by nonradioactive isotope 10B that 
disintegrates into alpha particles and lithium nuclei that cause non 
reparable damage to the cell where they were generated.[4] The 
low range of the charged particles permits the selective damage 
of tumour cells without affecting adjacent healthy cells if 10B atoms 
are selectively accumulated in the intracellular space of tumour 
cells. This makes BNCT a promising option for the treatment of 
infiltrating tumours and disseminated metastases that cannot be 
treated by methods requiring a precise localization of the mass, 
such as surgery or conventional radiotherapy.[5] It has been 
estimated that approximately 10-30  μg of 10B per gram of tumour 
mass are needed to deliver therapeutic dose of radiation to the 
tumour mass using an irradiation time shorter than a hour which 
allows not to exceed the tolerance dose in normal tissues.[6] The 
delivery of boron should be as selective as possible to tumour in 
order to increase the amount of internalized B in neoplastic cells 
and at the same time to minimize uptake in surrounding healthy 
tissues and permanence in blood which could create damages to 
normal organs and vessels. Currently, two BNCT drugs are 
available for clinical investigation namely: i) L-
paraboronophenylalanine (BPA), that has been used in clinical 
trials to treat glioblastoma,[7] head and neck recurrent cancer [8] 
and melanoma [9] and ii) sodium mercaptoundecahydro-closo-
dodecaborate (BSH) that has been investigated for the treatment 
of malignant glioma.[10] Despite their clinical use, both BPA and 
BSH show low cell targeting selectivity and great efforts have 
been made by several research groups to develop new and more 
selective boron delivery agents.[11] 
In this study, the stable adduct formed by boric acid, curcumin and 
oxalic acid (Rubrocurcumin)[12] has been exploited to combine 
BNCT with the anti-cancer activity of curcumin. Curcumin is a 
natural polyphenolic compound showing a wide range of 
pharmacological activities.[13] It has been proposed as therapeutic 
agent  as it showed antitumour activity in vitro and in animal 
models through the modulation or inhibition of multiple molecular 
pathways.[14] Furthermore, it has been recently reported that 
curcumin acts as an efficient radiosensitizer due the upregulation 
of genes responsible for cell death.[15]  Another important property 
is that, unlike other known chemotherapeutic compounds, 
curcumin does not cause any damage to the normal cells[16] and, 
in some cases, curcumin has also been shown to protect normal 
organs such as liver, kidney, oral mucosa, and heart from 
chemotherapy and radiotherapy-induced toxicity.[15] The formation 
of stable red complexes between B and curcumin has been 
exploited for the spectrophotometric detection of trace amount of 
B in various media, including biological materials (e.g. food-stuff, 
plants and blood plasma), natural water and sea water, soil, iron 
and steel, as well as material relevant to nuclear technology.[17] 
Moreover, promising medicinal applications of metal curcumin 
complexes have been reported.[18] The factor that limits the use of 
free curcumin and its complexes for tumour therapy is its low 
solubility in water, which in turn limits its bioavailability when 
administered orally. To this purpose, nanotechnology-based 




tumour sites along with appropriate curcumin functionalization for 
example with PEG chains.[20]  
Poly (lactic-co-glycolic acid) (PLGA) is one of the most effective 
biodegradable polymeric nanoparticles (NPs). It has been 
approved by the US FDA as drug delivery system due to its 
controlled and sustained-release properties, low toxicity, and 
biocompatibility with tissue and cells.[21] In this study, curcumin-
boron complexes (RbCur) have been loaded into folate-targeted 
PLGA nanoparticles (PLGA-NP-Folate)(Figure 1) together with an 
amphiphilic Gd based Magnetic Resonance Imaging (MRI) 




Figure 1: Schematic representation of folate conjugated PLGA 
RbCur/Gd nanoparticles (PLGA-NP-Folate) 
This novel theranostic agent allows i) to maximize the selective 
uptake of B atoms from tumour cells by targeting folate receptors 
alpha (FRA) and ii) to quantify B distribution in the tumour and in 
other tissues indirectly  by means of MRI response. To date a non-
invasive and repeatable in vivo B detection method is not 
available, even if it is well established that the measurement of 
local B concentration is crucial to determine the optimal neutron 
irradiation time, to calculate the delivered radiation dose and to 
evaluate the best irradiation time and duration.[23] Moreover, 157Gd 
is the second most studied element to perform NCT, as a 
consequence of its high cross section for the capture of low-
energy neutrons. The biological efficacy of Gd-based NCT is 
mainly due to the Auger electron cascade induced by the internal 
conversion process that occur in competition with the gamma-ray 
emission upon the neutron capture reaction from the 157Gd 
isotope. The energy associated to the Auger electrons is 0.6% of 
the total emitted energy (7.94 MeV). Despite the low energy these 
electrons may give strong cytotoxic effects when the 157Gds are 
very close to the cellular DNA. [5,24] In addition, Gd neutron capture 
results also in a release of long range rays which can be 
advantageous to damage also resistant cells not internalizing 
enough B/Gd to perform an effective therapy.[25] In this particular 
case, the location of the element is not critical with regard to target 
cell due to their longer ranges. Having BNCT and Gd-NCT 
different mechanisms of action, one expects advantages from 
their combined use. [26] One straightforward route dealt with the 
simultaneous administration of two NCT agents, one carrying 10B, 
the other 157Gd, but this approach has the disadvantage that their 
uptake and distribution within the tumour may be quite different. 
In this study, 10B and 157Gd are loaded in the same nanoparticle 
thus permitting their simultaneous distribution.  The eventual 
increment of the dose due to the 157Gd capture reaction is herein 
analysed and discussed. 
Results and Discussion 
Synthesis of the Boron/Curcumin dual agent Rubrocurcumin 
(RbCur) (Figure 2) has been performed by reacting boric acid, 
curcumin and oxalic acid according to the procedure described by 
Sui Z et al.[12] The complex has been characterized by UV-VIS 
spectrophotometry and by 1H-NMR. Figure 3 shows that after the 
complex formation, the curcumin peak at 430nm in the parent 
compound is shifted to 545nm, where RbCur exhibits its 









Figure 3: UV-VIS spectra of curcumin and Rubrocurcumin 
acquired in ethanol at 10 µM concentration. 
Synthesis of PLGA nanoparticles 
The methodology to obtain Folate conjugated and non-
conjugated PLGA nanoparticles (PLGA-NP-Folate and PLGA-
NP-Ctrl, respectively) was based on the o/w emulsion solvent 
extraction method.[21] The organic phase was prepared dissolving 
PLGA RG 503H, RbCur, Gd-DOTAMA, pegylated phospholipid 
(DSPE-PEG(2000)methoxy) in 9:1 chloroform: methanol. For the 
preparation of PLGA-NP-Folate DSPE-PEG(2000)Folate was 
added to the organic phase. The water phase consisted of a 
poly(vinyl alcohol) (PVA) aqueous solution (3% w/v). PVA is the 
most commonly used emulsifier for the preparation of these PLGA 
based NP because it yields particles that are relatively uniform, 
small sized, and easy to be re-dispersed in water.[27] To obtain 
PLGA nanoparticles, the organic phase was added to the 
aqueous phase and the mixture was sonicated for 5 minutes. 
Then, the solidification of nanospheres was obtained by organic 
solvent evaporation from the o/w emulsion. The organic solvent 
was slowly removed under vacuum in a rotary evaporator (2.5 h).  
 
 
Table 1: Encapsulation yields of the RbCur and Gd-DOTAMA in 
PLGA-NP-Ctrl and PLGA-NP-Folate are reported together with 
their size (nm), their relaxivity (mM-1sec-1 21.5 MHz 25°C) and 
their polydispersity index (PDI).   
 
PLGA 
NP Encapsulation yield (%) Gd-DOTAMA              RbCur Relaxivity (mM-1sec-1) 
Size 
(nm) PDI 
Ctrl 71 ± 7 12.6 ± 4.3 26.1±1.7 144±3 0.099 
Folate 73 ± 15 10.4 ± 2.8 27.8±1.7 149±3 0.138 
 
 
As reported in Table 1, the average hydrodynamic diameters of 
folate targeted and un-targeted PLGA nanoparticles obtained by 
dynamic light scattering (DLS) measurements show a 
homogeneous particle size distribution, of about 150 nm, with a 
polydispersity index (PDI) < 0.2. The encapsulation yields of Gd-
DOTAMA were significantly higher than RbCur. An additional 
amount of curcumin (equal to the 43% w/w of the loaded RbCur) 
was found in the PLGA-NPs due to the partial dissociation of the 
RbCur complex, during the loading protocol, as shown in the UV-
VIS spectrum acquired immediately after its preparation (Figure 
4). However, the remaining RbCur complex encapsulated in the 
PLGA-NP was stable at 4°C for 2 weeks and all the following 
experiments were performed within this time. The Gd complexes 
incorporated in PLGA-NP endowed the system with a high 
relaxivity (26-28 mM-1sec-1 at 21.5 MHz, 25°C) as a consequence 
of the partial exposition of the hydrophilic portion of the complex 
to the particle external surface and the partial water diffusion 






Figure 4: UV-VIS spectrum of RbCur loaded in PLGA-NP-Ctrl 
acquired in ethanol. 
Stability of PLGA nanoparticles. The stability of PLGA 
nanoparticles was evaluated measuring by ICP-MS the release of 
B and Gd-DOTAMA from PLGA-NP-Ctrl and PLGA-NP-Folate. To 
this purpose, freshly prepared nanoparticle suspensions were 
dialyzed at 37°C against 40mL of HBS buffer for 5 days. Figure 5 
shows that the amount of B released is about the 50% after 6h 
and it increased to 60% after 24 hours. In general, drug release 
depends upon: i) solubility, diffusion and biodegradation of the 
matrix materials; ii) loading efficiency of the drug and iii) size of 
the nanoparticles.[29] The faster B release from the NP herein 
observed is the consequence of the relatively low stability of 
RbCur at 37°C with the consequent release of boric acid. The 
longitudinal water proton relaxation rate (R1) measured over 5 
days (Figure 5) showed only minor changes, suggesting a 
negligible release of Gd-DOTAMA over the observed time period. 
The relatively fast release of B from the nanocage forced us to 
maintain short incubation time (6h) in the cell uptake experiments 





Figure 5: Evaluation of the stability of PLGA-NP-Ctrl and PLGA-
NP-Folate loaded with RbCur and Gd-DOTAMA by measuring B 
and Gd concentrations in the NP solution over 5 days of dialysis 





Folate targeting efficiency of PLGA-NPs and MRI 
visualization.  
Folate-conjugated PLGA-NP have been tested for their efficacy in 
targeting Human Ovarian Cancer Cells (IGROV-1) 
overexpressing FRA.[30]  Folic acid is a typical cell-targeting agent, 
because of its high affinity for FRA that is known to be 
overexpressed on the surface of many human cancer cells [31] and 
capture FA from the extracellular milieu and transport it inside the 
cell via a receptor-mediated endocytosis. There are different 
hypothesis concerning the precise mechanism of FR trafficking 
into cells. As reported by Stella et al. .[32] and Lu et al, .[32], folate-
conjugated nanoparticles represent a multivalent form of the 
ligand folic acid. Since FRA are often disposed in clusters, 
conjugated nanoparticles could display a multivalent stronger 
interaction with the receptors and they can’t be displaced by free 
folic acid. 
Gd and B moles internalized by IGROV-1 cells, measured by ICP-
MS after 6h incubation in the presence of increased concentration 
of PLGA-Folate nanoparticles were compared with those 
obtained using non-targeted ones. Figure 6 shows that Folate 
targeted NP reach a complete saturation when their concentration 
in the incubation medium was higher than 100 μM in Gd. This 
demonstrates a high affinity of Folate-targeted NP for the FRA 
and a negligible non-specific cell binding of non-targeted NP.  The 
results obtained with IGROV-1 cells were compared with those 
obtained with human breast cancer cells (MCF-7) don’t 
expressing FRA[32],  with healthy mammary gland mouse cells 
(NMuMg) and embryo fibroblast cells (BALB/C 3T3) using the 
same incubation protocol. Figure 6 shows that the internalization 
of PLGA-NP-Folate by MCF-7, NMuMg and 3T3 is negligible in 
the range of the concentrations considered. These observations 
suggested that the selectivity of the PLGA-NP-Folate is directed 
only to tumour cells overexpressing FRA and that their targeted 
intracellular delivery takes place via a folate receptor mediated 
endocytosis mechanism.  
 
Figure 6: Uptake of PLGA-NP-Ctrl and PLGA-NP-Folate by 
IGROV-1, MCF-7, NMuMg and 3T3. Cells were incubated 6 hours 
at 37°C in the presence of increasing concentrations of PLGA-
NP-Ctrl and PLGA-NP-Folate (25 – 200 μM Gd). The amount of 
Gd taken-up by cells has been determined by ICP-MS and it was 




The amount of B and Gd internalized by IGROV-1 cells incubated 
with PLGA-NP-Folate (100 M Gd), measured by ICP-MS, was of 
6.4 and 78.6 µg/g of B and Gd, respectively. Finally, MRI images 
were acquired after incubating PLGA nanoparticles on IGROV-1 
cells at a concentration of 100µM Gd. As shown in Figure 7, the 
T1 weighted MR image acquired at 7 T of a phantom made of 
glass capillaries containing cell pellets, the recorded signal 
intensity (SI) of PLGA-NP-Folate in IGROV-1 cells was 
significantly higher with respect to non-targeted one. This 
observation confirms the specific accumulation of folate targeted 





Figure 7: T1-weighted spin echo MRI image (measured at 7 T) of 
an agar phantom containing untreated IGROV-1 cells (1) or cells 
incubated with PLGA-NP-Ctrl (2) or PLGA-NP-Folate (3) for 6 h 
at 37°C at a 100 μM Gd concentration. 
 
In order to assess whether the combination of Gd/B-NCT and  
curcumin results in an improvement of the treatment outcome 
(with respect to BNCT given as monotherapy), the clinically used 
B delivery agent boronophenylalanine (BPA) (Figure 8A) was 
exploited as an alternative B source. For comparison, IGROV-1 
cells were incubated for 3h in the presence of increasing BPA 
concentrations (10-500M B) (Figure 8B).  As expected, the 
internalization of PLGA-NP-Folate (28-220µM B) was significantly 
more efficient with respect to BPA uptake by IGROV-1 cells and 
6.4 µg/g of B was reached after 6h incubation. This amount of B 
was significantly lower than the minimum B concentration 
necessary to perform BNCT but since the B was confined within 
the cells resulted high enough to produce a neutron capture 
reaction. Only after incubation of BPA at 500 µM B, the 
concentration of B internalized by cells was 6.4 ug/g whereas for 
PLGA-NP-Folate was sufficient a five times lower concentration 
in the incubation medium.  
 
 
Figure 8: (A) Chemical structure of BPA; (B) B internalization in 
IGROV-1 cells on incubation in the presence of increasing BPA 
concentrations (100 – 500 µM B) for 3h at 37°C  or with  PLGA-
NP-Ctrl or PLGA-NP-Folate (28 – 220 µM B) for 6 h at 37°C.  
 
This observation confirmed that the use of targeted nanoparticles 
allowed the accumulation of B in tumour cells without using huge 
doses of B carrier; doses that can enhance the non-specific 
uptake by healthy tissues.  
   
BNCT treatment of IGROV-1 cells. To improve NCT 
performance, PLGA-NP-Folate were prepared using Gd-
DOTAMA and RbCur synthesized with 157Gd (92.3%) and 10B 
(99 %) enriched isotopes, respectively.  
Three groups of IGROV-1 cells were considered: untreated cells 
irradiated only with thermal neutrons (2); BPA treated cells then 
irradiated with neutrons (BNCT-group) (4); and PLGA-NP-Folate 
treated cells then irradiated with neutrons (Gd-BNCT-group) (6) 
and compared with the not irradiated analogous (1) (3) (5), 
respectively. Under these conditions both treated cell groups 
internalized the same amount of 10B (6.4 µg/g).  
Groups (2), (4) and (6) were irradiated for 15’ in the thermal 
column of the TRIGA Mark II reactor at the University of Pavia 
(Reactor Power 30kW).  
IGROV-1 cells treated with PLGA-NP-Folate (5-6) and BPA (3-4) 
were incubated for 6h with PLGA-NP-Folate (130µM B) and 3h 
with BPA 500µM B, respectively. Figure 9A shows the percent of 
cells that survived to neutron irradiation (2,4,6) with respect the 
non-irradiated groups (1,3,5). We can observe that the number of 
viable cells was significantly lower in the case of cells internalizing 
PLGA-NP-Folate (6), with respect cells internalizing BPA (4) (with 
the same 10B amount), both irradiated with neutrons as a 
consequence of the additional cytotoxic effect of curcumin. 
Whereas the difference between group 5 and 6 is less evident and 
not significant. Interestingly, the results changed by considering 
the proliferation rate of cells surviving to irradiation (Figure 9B). 
Figure 9B shows that both cells not irradiated (3) and irradiated 
(4) after BPA treatment, together with cells treated with PLGA-
NP-Folate (without irradiation) (5) restart to proliferate rapidly, 72 
h after the irradiation, as the untreated controls (1). On the 
contrary, cells treated with PLGA-NP-Folate after neutron 
irradiation (6) showed a complete inhibition of proliferation.  
The radiation dose absorbed by cells treated with BPA and PLGA-
NP-Folate reaching a 10B concentration of 6.4 µg/g ranges 
between 4.55 and 4.57 Gy. The total absorbed doses obtained in 
presence of 157Gd through PLGA-NP Folate increases very 
modestly of only 0.07% by assuming a non-nuclear Gd 
accumulation.  Anyway, it must be noticed that the 86% of the 
small increment seen with 157Gd is due to the short range IC and 
Auger electrons. Consequently, it cannot be excluded that a 
measurable increment in term of cell death would be visible once 
the co-localization of 157Gd nuclei and cell DNA is guaranteed. 
Finally, it is worth to be noticed that in the two NCT groups (cells 
exposed to BPA or PLGA-NP Folate) about 45% of the total dose 
is due to the secondary radiations emitted in the neutron capture 
reaction of 10B while in the third irradiated group (neutron only) 
receiving about 2.5 Gy, up to 91% of the total dose is imparted by 
gamma rays coming from the neutron capture reaction of 1H in the 
cell layer and from the photon background characterizing the 
irradiation position inside the thermal column. 
 
Figure 9: (A) Percentage of IGROV-1 cells that survived the 
BNCT treatment. (B) Proliferation curves of IGROV-1 cells re-
plated one day after the BNCT treatment.  
  
Although 157Gd intracellular concentration was not sufficient to 
produce an increment in term of cell damage after neutron 
irradiation, the presence of curcumin before and during the 
neutron exposure resulted in an improvement of the treatment 
outcome with respect to BNCT used as monotherapy with the 
same [B] µg/g accumulated using BPA alone as B source. The 
presence of curcumin allowed to increase cell mortality and 
decrease significantly cell proliferation of the surviving cells, 
despite the B concentration was under the established threshold 
for an effective BNCT treatment (10-30 µg/g). Due to the 
difficulties encountered to obtain such high B concentrations, 
requiring patient perfusion with high concentrated solution of BPA 








In this work, the antitumour activity arising from Gd and B-NCT 
and curcumin was tested on IGROV-1 ovarian cancer cells, using 
an innovative folate targeted PLGA nanoparticle containing both 
Gd and the curcumin-boron complex RbCur. This new 
nanoparticle has shown to be an efficient carrier by folate 
receptors and can be exploited for the measurement of Gd and 
indirectly B concentrations by MRI, opening new perspectives in 




Curcumin, boric acid, oxalic acid, poly(D,L-lactide-co-glicolide) 
(PLGA) 50:50 (Resomer RG 503 H), molecular weight (Mw) 
30000-60000 Da and Poly(vinyl alcohol) (Mowiol 4-88), Mw 
31000 Da were provided by Sigma-Aldrich (St. Louis, Missouri, 
USA). DSPE-PEG(2000){1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] 
ammonium salt} and DSPE-PEG(2000)folate {1,2-distearoyl-sn-
glycero-3 phosphoethanolamine-N-[folate(polyethylene glycol)-
2000] ammonium salt} were purchased from Avanti Polar Lipids 
(Alabaster, AL) The lipophilic Gd-DOTAMA was synthesized 
according to a previously reported procedure.[22] 
Rubrocurcumin synthesis and characterization. A suspension 
of curcumin (369 mg, 1 mmol), boric acid (62 mg, 1 mmol) and 
oxalic acid (91 mg, 1 mmol) in 40 mL of toluene was stirred and 
heated under reflux for 16 hours using a Dean-Stark trap. After 
cooling, the red precipitate was collected and washed several 
times with toluene and ethyl acetate before drying under reduced 
pressure (261 mg, Yield 56%). UV max= 545 nm. MS (ESI+): 
m/z: calcd for C23H19BO10 [M+H]+ 466.1; found: 466.9. The 
compound showed sufficient purity (85%) determined by 1H-NMR 
spectroscopy, (600 MHz, acetone-d6) 3.93 (s, 6H, OCH3), 6.55 
(s, 1H, CH), 6.96 (d, 2H, J= 7.8 Hz, Ar), 7.07 (d, 2H, J= 15.7 Hz, 
Ar) 7.42 (d, 2H, J= 8.3 Hz, Ar) 7.51 (s, 2H, Ar), 8.11 (d, 2H, J= 
15.4Hz, Ar), 8.83 (br, OH). (see supplementary material).    
1H NMR spectra were acquired on a Bruker Avance 600 
spectrometer (Bruker BioSpin, Ettlingen, Germany). Mass 
spectral analysis were performed with a Waters 3100 Mass 
Spectrometer ESI(+) mode. 
Synthesis of PLGA nanoparticles. Two different nanospheres 
were prepared: one targeted with folate and the other non-
targeted and used as control. Nanospheres were obtained using 
the oil-in-water emulsion solvent extraction method. Folate-
targeted nanoparticles were prepared dissolving 25 mg of PLGA, 
1.2 mg of DSPE-PEG(2000)folate, 1 mg of DSPE-
PEG(2000)methoxy, 3.2 mg of Gd-DOTAMA and 6 mg of RbCur 
in 600 ul (9:1 chloroform:methanol, phase 1); non-targeted 
nanoparticles were prepared dissolving 25 mg of PLGA, 2.2 mg 
of DSPE-PEG(2000)methoxy, 3.2 mg of Gd-DOTAMA and 6 mg 
of RbCur in 600 ul (9:1 chloroform:methanol, phase 1). Phase 2 
consisted for both nanoparticles of 3% w/v PVA aqueous solution 
(3 mL). Phase 1 was added into phase 2 drop by drop and the 
obtained emulsion was sonicated (Bandelin electronic, Berlin, 
Germany) in ice at 100% power for 5 minutes. Immediately, the 
emulsion was put into a rotary evaporator (at 740 mmHg and 30 
rpm) for 150 minutes to remove the organic solvent. After the 
evaporation step, the untrapped compounds were removed by 
dialysis (molecular weight cut-off of 14000 Da) at 4°C in 1 L of 
isotonic NaCl/Hepes buffer (HBS). The excess of PVA was 
removed by washing the emulsion with a vivaspin 20 filter 
(Sartorius AG, Goettingen, Germany, cut-off of 1 x 106 Da). Gd 
and B amount incorporated in PLGA nanoparticles were 
measured by inductively coupled plasma mass spectrometry 
(ICP-MS; element-2; Thermo-Finnigan, Rodano (MI), Italy) after 
sample digestion performed with concentrated HNO3 (70%, 1 mL) 
under microwave heating (Milestone MicroSYNTH Microwave 
labstation). The amount of Gd was double checked by 1H nuclear 
magnetic resonance R1 measurement at 21.5 MHz, 25°C (Stelar 
Spinmaster, Mede, Italy) of the mineralized complex solution (in 6 
mol/L HCl at 120°C for 16 h). The hydrated mean diameter of 
nanoparticles was determined using a dynamic light scattering 
(DLS) Malvern Zetasizer 3000HS (Malvern, U.K.) All samples 
were analyzed at 25°C in filtered (cut-off, 200 nm) HBS buffer (pH 
7.4). The amount of RbCur and curcumin loaded into the PLGA-
NPs were determined acquiring a UV-VIS spectrum in the range 
of 360-700 nm in ethanol. According to the calibration curve of 
RbCur (Y=0.1303X-0.015 (µg/mL at  545nm)) and curcumin 
(Y=0.15582X (µg/mL at 430nm)) the encapsulation yield was 
calculated following  equation 1: 
  
% Encapsulation: (RbCur encapsulated / RbCur total) x 100        (Eq. 1) 
 
where: RbCurencapsulated is the amount of RbCur measured after the 
NP preparation, and RbCurtotal is the total amount of RbCur used 
to prepare the NP. Nanoparticles were stored under dark at 4°C 
until further analysis.  
  
Stability of PLGA nanoparticles. To perform stability test, 2.5 
mL of PLGA-NP-Ctrl and PLGA-NP-Folate at a 0.2 mM Gd 
concentration in HBS buffer, were dialyzed at 37°C (cut-off= 
14000 Da) in 40mL HBS for 5 days. At different time intervals, 
200uL of the dialyzed NP solution was taken to measure Gd and  
B concentrations. The 40mL HBS buffer was renewed at each 
drawing. Gd and B amount were measured by ICP-MS. The 
experiment was performed in duplicate. 
Cell culture and uptake experiments. Human ovarian 
carcinoma cell line (IGROV-1) was kindly provided by Dr Claudia 
Cabella (Bracco Imaging, Colleretto Giacosa TO). IGROV-1 cells 
were cultured in RPMI (Lonza) supplemented with 10% (v/v) FBS, 
2 mM glutamine, 100 U mL−1 penicillin, and 100 U mL−1 
streptomycin. Human breast cancer cells (MCF-7) and murine 
embryo fibroblast cells (BALB/C 3T3) were obtained from the 
ATCC and NMuMG cell line derived from a healthy mouse 
mammary gland was kindly provided by Prof. Lollini PL, University 
of Bologna. MCF-7 were cultured in EMEM (Lonza) 
supplemented with 10% (v/v) FBS, 2mM glutamine, 100 U mL−1 
penicillin, and 100 U mL−1 streptomycin, 1mM sodium pyruvate 
and non-essential amino acids, 10 µg/mL insulin (Sigma). NMuMg 
were cultured in RPMI (Lonza) supplemented with 10% (v/v) FBS, 
2mM glutamine, 100 U mL−1 penicillin, and 100 U mL−1 
streptomycin and 10 µg/mL insulin (Sigma).  BALB/C 3T3 were 
cultured in DMEM (Lonza) supplemented with 10% (v/v) FBS, 
4mM glutamine, 100 U mL−1 penicillin, and 100 U mL−1 
streptomycin. Cells were incubated at 37 °C in a humidified 
atmosphere of 5% CO2. For the in vitro uptake experiments, 4.5 
× 105 of IGROV-1, 6 x 105 MCF7, 4 x 105 NMumg and 6 x105 3T3 
BALB/C were seeded in 6 cm diameter culture dishes. After 24h, 
IGROV-1 medium was removed and it was replaced with RPMI 
w/o folate to increase folate receptor expression. After other 24h, 
all the cells were incubated 6h in folate free medium with 
increasing concentration (25-200 µM in Gd) of PLGA-NP-Ctrl or 
PLGA-NP-Folate. At the end of incubation, cells were washed 
three times with 5 mL ice-cold PBS, detached with 0.05% trypsin 
and 0.02% EDTA in PBS. IGROV-1 cells were further transferred 
into glass capillaries for MRI analysis (see below). For the BPA 
uptake 4.5 × 105 of IGROV-1 were seeded in 6 cm diameter 
culture dishes. After 48h the medium was removed and replaced 
with EBSS buffer in the presence of increasing concentrations of 
BPA (100-500µM B) for 3h. At the end of incubation, cells were 
washed three times with 5 mL ice-cold PBS, detached with 0.05% 
trypsin and 0.02% EDTA in PBS. Finally, all cell samples were 
transferred in falcon tubes and sonicated at 30% of power for 30 
sec in ice; their total cell protein concentrations were determined 
by a commercial Bradford assay (Biorad, Hercules, CA, USA). Gd 
and B content in the cell samples was determined by ICP-MS and 
they were normalized by the protein content of each cell sample 
that was correlated to the number of cells by means of a 
calibration curve (mg of protein /n° of cells). The µg of B and Gd 
for g of tissue were thus calculated considering that 1 g of tissue 
contains 1x109 cells.  
MRI. MR images were acquired at 7 T on a Bruker Avance 300 
spectrometer equipped with a Micro 2.5 microimaging probe 
(Bruker BioSpin, Ettlingen, Germany) using a birdcage resonator 
of 10 mm inner diameter. For recording MR images in vitro, cells 
were pelleted at the bottom of glass capillaries placed in a 
phantom embedded of high gelling agarose gel (1% w/v in PBS). 
MR images were acquired using a standard T1 weighted multislice 
spin echo sequence, using the following parameters: TR/TE/NEX 
250/4/6, resolution 78 μm, slice thickness 1 mm.  
Cell irradiation. Eight flasks, three with IGROV-1 cells previously 
incubated for 6h in the presence of PLGA-NP-Folate, 130 µM B, 
three incubated for 3h with BPA at 500 µM B concentration and 
two non-treated control cells were irradiated in the thermal column 
of the TRIGA Mark II reactor at the University of Pavia, Italy. Cells 
incubated in the presence of PLGA nanoparticles and BPA were 
washed with cold PBS before irradiation. At the end of the 
irradiation, the medium was removed, it was replaced with fresh 
RPMI and flasks were placed at 37 °C in a humidified atmosphere 
of 5% CO2. 
The irradiation position was previously characterized from the 
point of view of neutron flux distribution by means of thin activation 
foils.[34] At a reactor power of 250 kW the thermal neutron flux in 
air at that position is (1.20 ± 0.10) × 1010 cm−2 s−1, while the 
epithermal and fast components are at least two orders of 
magnitude lower. The flux is roughly constant (less than 1%) 
along the vertical direction, thus the flasks were superposed and 
irradiated at the same time. The irradiation time has been fixed at 
15 minutes at a reactor power of 30 kW, corresponding to a 
thermal neutron fluence of 1.30 × 1012 cm−2 
Proliferation assay. The day after irradiation cells were detached 
with 0.02% EDTA and the trypan blue exclusion test of cell 
viability was performed. Then, around 6 × 105 IGROV-1 cells from 
each differently treated flask were seeded in 10 cm diameter 
culture dishes. After 1, 2, 3 and 4 days, cells were washed with 
PBS, detached with 0.05% trypsin and 0.02% EDTA in PBS and 
transferred into falcon tubes. Then, cells were sonicated for 30 
sec at 30% power in ice and the total cell protein concentration 
from cell lysates was determined by the Bradford method, using 
bovine serum albumin as a standard. 
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“Theranostic” Nanoparticles loaded with imaging probes and rubrocurcumin for a combined cancer therapy.  




Innovative theranostic agent based on folate targeted PLGA nanoparticles loaded with a boron-curcumin complex (Rubrocurcumin) and the MRI 
contrast agent Gd-DOTAMA to combine BNCT with the anti-cancer activity of curcumin for the imaging guided treatment of human ovarian cancer 
cells (IGROV-1). 
 
